Abstract
s / Pancreatology 12 (2012) 502–597 525 disease were 61.4% (CI 51-70) and 24.3% (CI 16-33), respectively. Treatment-related grade 3-4 toxicity was 34.6% (CI 24-46). At restaging following neoadjuvant therapy, 67.5% of patients (CI 54-78) underwent surgery, and 80.3% of them (CI 67-88) underwent resection. R0 resections amounted to 82.1 % (CI 74-88). Estimated 1and 2-year survival probabilities after resection were 52.1% (CI 33-70) and 44.9 % (CI 21-71). Conclusion: Our data cast some concern on the value of neoadjuvant therapy for patients with BR pancreatic cancers: if the intent of therapy were to induce tumor shrinkage and to allow curative surgery, this is only accomplished in one out of 7 patients; moreover, two thirds of patients could have been explored at their initial presentation, as they underwent surgery despite anunsuccessful response to therapy. The only benefit of this approach seems to be sparing surgery for patientswith progressive disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
